KR102225371B1 - 플리나불린 및 탁산의 조합에 의한 암 치료 - Google Patents

플리나불린 및 탁산의 조합에 의한 암 치료 Download PDF

Info

Publication number
KR102225371B1
KR102225371B1 KR1020167012255A KR20167012255A KR102225371B1 KR 102225371 B1 KR102225371 B1 KR 102225371B1 KR 1020167012255 A KR1020167012255 A KR 1020167012255A KR 20167012255 A KR20167012255 A KR 20167012255A KR 102225371 B1 KR102225371 B1 KR 102225371B1
Authority
KR
South Korea
Prior art keywords
docetaxel
plinabulin
tumor
treatment
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020167012255A
Other languages
English (en)
Korean (ko)
Other versions
KR20160078987A (ko
Inventor
황 란
Original Assignee
비욘드스프링인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52812462&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102225371(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 비욘드스프링인크. filed Critical 비욘드스프링인크.
Publication of KR20160078987A publication Critical patent/KR20160078987A/ko
Application granted granted Critical
Publication of KR102225371B1 publication Critical patent/KR102225371B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020167012255A 2013-10-11 2013-10-11 플리나불린 및 탁산의 조합에 의한 암 치료 Active KR102225371B1 (ko)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2013/085075 WO2015051543A1 (en) 2013-10-11 2013-10-11 Cancer treatment with combination of plinabulin and taxane

Publications (2)

Publication Number Publication Date
KR20160078987A KR20160078987A (ko) 2016-07-05
KR102225371B1 true KR102225371B1 (ko) 2021-03-10

Family

ID=52812462

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167012255A Active KR102225371B1 (ko) 2013-10-11 2013-10-11 플리나불린 및 탁산의 조합에 의한 암 치료

Country Status (18)

Country Link
US (2) US10596169B2 (enExample)
EP (1) EP3076972B1 (enExample)
JP (1) JP6411523B2 (enExample)
KR (1) KR102225371B1 (enExample)
CN (1) CN105705148B (enExample)
AU (1) AU2013402794B2 (enExample)
BR (1) BR112016007946A2 (enExample)
CA (1) CA2926771C (enExample)
DK (1) DK3076972T3 (enExample)
ES (1) ES2902665T3 (enExample)
IL (1) IL244984B (enExample)
MX (1) MX384751B (enExample)
MY (1) MY185650A (enExample)
NZ (1) NZ719049A (enExample)
RU (1) RU2662298C2 (enExample)
SG (1) SG11201602637QA (enExample)
WO (1) WO2015051543A1 (enExample)
ZA (1) ZA201602380B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL286282B2 (en) * 2015-02-12 2023-10-01 Beyondspring Pharmaceuticals Inc Use of palinabolin in combination with immune checkpoint inhibitors
HK1249052A1 (zh) * 2015-03-06 2018-10-26 BeyondSpring Pharmaceuticals Inc. 治疗与ras突变相关的癌症的方法
EP3265091A4 (en) * 2015-03-06 2018-08-01 Beyondspring Pharmaceuticals Inc. Method of treating a brain tumor
MX376122B (es) * 2015-07-13 2025-03-07 Beyondspring Pharmaceuticals Inc Composiciones de plinabulina.
SG11201806583XA (en) 2016-02-08 2018-09-27 Beyondspring Pharmaceuticals Inc Compositions containing tucaresol or its analogs
BR112018074990A2 (pt) * 2016-06-06 2019-03-12 Beyondspring Pharmaceuticals, Inc. composição, usos e método para reduzir neutropenia
US11633393B2 (en) 2017-01-06 2023-04-25 Beyondspring Pharmaceuticals, Inc. Tubulin binding compounds and therapeutic use thereof
EP3576733A4 (en) * 2017-02-01 2020-11-25 Beyondspring Pharmaceuticals, Inc. NEUTROPENIA REDUCTION METHOD
BR112019018880A2 (pt) * 2017-03-13 2020-04-14 Beyondspring Pharmaceuticals Inc composições de plinabulina e seu uso
CN109498627B (zh) * 2017-09-15 2021-06-04 深圳华大海洋科技有限公司 一种治疗肿瘤的药物组合物及其应用
KR20200112881A (ko) 2018-01-24 2020-10-05 비욘드스프링 파마수티컬스, 인코포레이티드. 플리나불린의 투여를 통해 혈소판감소증을 감소시키는 조성물 및 방법
CN112105363A (zh) * 2018-02-01 2020-12-18 大连万春布林医药有限公司 用于通过施用普那布林和g-csf剂来减少化学疗法诱导的嗜中性白血球减少症的组合物和方法
CN108524442B (zh) * 2018-06-05 2022-01-28 深圳海王医药科技研究院有限公司 一种抗肿瘤药物的注射剂及其制备方法
JP2018199726A (ja) * 2018-09-26 2018-12-20 ビヨンドスプリング インコーポレイテッド プリナブリン及びタキサンの組合せがん治療
JP2022513038A (ja) * 2018-11-14 2022-02-07 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド チューブリン結合薬を使用する癌の治療方法
CN110507653B (zh) * 2019-08-02 2022-12-02 北京赛而生物药业有限公司 多潘立酮及其与紫杉醇联用在制备治疗癌症的药物中的应用
US20240299377A1 (en) * 2019-10-15 2024-09-12 Beyondspring Pharmaceuticals, Inc. Methods and compositions for treating iron disorders
EP4319751A4 (en) 2021-04-09 2025-02-26 Beyondspring Pharmaceuticals, Inc. THERAPEUTIC COMPOSITIONS AND METHODS FOR THE TREATING OF TUMORS
CN113456643B (zh) * 2021-08-11 2022-04-01 遵义医科大学 一种含普那布林的药物组合及其应用
CN117860672A (zh) * 2022-10-11 2024-04-12 大连万春布林医药有限公司 一种普那布林胶束组合物及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005077940A1 (en) 2004-02-04 2005-08-25 Nereus Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7141603B2 (en) 1999-02-19 2006-11-28 The Regents Of The University California Antitumor agents
US7012100B1 (en) 2002-06-04 2006-03-14 Avolix Pharmaceuticals, Inc. Cell migration inhibiting compositions and methods and compositions for treating cancer
US7919497B2 (en) 2002-08-02 2011-04-05 Nereus Pharmaceuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
DK1529044T5 (da) 2002-08-02 2008-04-21 Nereus Pharmaceuticals Inc Dehydrophenylahistiner og analoger deraf og syntesen af dehydrophenylahistiner og analoger deraf
GB0907551D0 (en) * 2009-05-01 2009-06-10 Univ Dundee Treatment or prophylaxis of proliferative conditions
WO2014160183A1 (en) 2013-03-13 2014-10-02 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Methods for modulating chemotherapeutic cytotoxicity

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005077940A1 (en) 2004-02-04 2005-08-25 Nereus Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
J. Clinical Oncology, 28, 15 Suppl., 7592, 2010.*
J. New Anticancer Agents, 3(30), 1069, 2011.

Also Published As

Publication number Publication date
WO2015051543A1 (en) 2015-04-16
JP2016536352A (ja) 2016-11-24
KR20160078987A (ko) 2016-07-05
MX384751B (es) 2025-03-14
MY185650A (en) 2021-05-27
AU2013402794B2 (en) 2020-02-27
CA2926771C (en) 2022-07-05
ES2902665T3 (es) 2022-03-29
JP6411523B2 (ja) 2018-10-24
AU2013402794A1 (en) 2016-05-12
DK3076972T3 (da) 2022-01-03
IL244984B (en) 2022-05-01
US10596169B2 (en) 2020-03-24
EP3076972A4 (en) 2017-12-20
RU2662298C2 (ru) 2018-07-25
US20200281921A1 (en) 2020-09-10
BR112016007946A2 (pt) 2017-09-12
CA2926771A1 (en) 2015-04-16
ZA201602380B (en) 2022-05-25
CN105705148A (zh) 2016-06-22
IL244984A0 (en) 2016-05-31
EP3076972B1 (en) 2021-10-06
SG11201602637QA (en) 2016-05-30
MX2016004441A (es) 2016-10-28
EP3076972A1 (en) 2016-10-12
CN105705148B (zh) 2021-03-23
WO2015051543A8 (en) 2016-04-21
US20160250209A1 (en) 2016-09-01
NZ719049A (en) 2020-06-26
RU2016112608A (ru) 2017-11-16

Similar Documents

Publication Publication Date Title
KR102225371B1 (ko) 플리나불린 및 탁산의 조합에 의한 암 치료
RU2640485C2 (ru) Комбинированное лечение рака
JP2020172487A (ja) トラスツズマブ−ｍｃｃ−ｄｍ１及びペルツズマブにより早期の乳癌を処置する方法
JP2012500180A5 (enExample)
JP2014132009A5 (enExample)
CN104997808A (zh) 用于治疗癌症的方法和组合物
WO2014142220A1 (ja) 抗腫瘍剤
CA3080644A1 (en) Use of parp inhibitor in treating chemotherapy-resistant ovarian cancer or breast cancer
JP2013521338A (ja) 小細胞肺癌を治療するための方法
Kollmannsberger et al. Temsirolimus in combination with carboplatin and paclitaxel in patients with advanced solid tumors: a NCIC-CTG, phase I, open-label dose-escalation study (IND 179)
US20190275021A1 (en) Use of combination of vegfr inhibitor and parp inhibitor in preparation of medicament for treating gastric cancer
KR20250168664A (ko) 바실루스 칼메트-구에린 요법에 무반응성인 고위험 근육 비침습성 방광암을 치료하는 방법에 사용하기 위한 젬시타빈
JP2018199726A (ja) プリナブリン及びタキサンの組合せがん治療
JP7445826B2 (ja) 固形腫瘍治療用医薬組成物
HK1229712B (en) Cancer treatment with combination of plinabulin and taxane
RU2777519C2 (ru) Применение ингибитора parp в лечении резистентного к химиотерапии рака яичников или рака молочной железы
WO2023039568A1 (en) Therapeutic combinations of orally administered paclitaxel, a p-gp inhibitor, and a checkpoint inhibitor for the treatment of solid tumors
HK40116298A (zh) 用於治疗实体瘤的口服施用紫杉醇、p-gp抑制剂和检查点抑制剂的治疗组合
CN121219284A (zh) 治疗具有促细胞分裂原活化蛋白激酶(mapk)通路改变的实体瘤的方法
WO2026037393A1 (zh) 一种抗体药物偶联物与酪氨酸激酶抑制剂的组合
JP2016104704A (ja) 抗腫瘍剤

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 6